DGAP-News

RedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference - Seite 3

refractory/relapsed diffuse large B-cell lymphoma was initiated in June
2015 at the Louisiana State University Health Sciences Center in New
Orleans and was recently amended to address overall recruitment prospects.
The study will now also include Kaposi sarcoma patients. The study is
supported by a grant from the NCI awarded to Apogee, with additional
support from RedHill.

A Phase Ib study to evaluate YELIVA(R) as a radioprotectant for prevention
of mucositis in head and neck cancer patients undergoing therapeutic
radiotherapy is planned to be initiated in the first half of 2017.

Additional Phase I/II studies with YELIVA(R) for other indications are in
various stages of preparation.

About YELIVA(R) (ABC294640):
YELIVA(R) (ABC294640) is a Phase II-stage, proprietary, first-in-class,
orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with
anti-cancer and anti-inflammatory activities. RedHill is pursuing with
YELIVA(R) multiple clinical programs in oncology, inflammatory and
gastrointestinal indications. By inhibiting the SK2 enzyme, YELIVA(R)
blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signaling
molecule that promotes cancer growth and pathological inflammation. SK2 is
an innovative molecular target for anticancer therapy because of its
critical role in catalyzing the formation of S1P, which is known to
regulate cell proliferation and activation of inflammatory pathways.
YELIVA(R) was originally developed by U.S.-based Apogee Biotechnology Corp.
and completed multiple successful pre-clinical studies in oncology,
inflammation, GI and radioprotection models, as well as the ABC-101 Phase I
clinical study in cancer patients with advanced solid tumors. The Phase I
study included the first-ever longitudinal analysis of plasma S1P levels as
a potential pharmacodynamic (PD) biomarker for activity of a sphingolipid-
targeted drug. The administration of YELIVA(R) resulted in a rapid and
pronounced decrease in S1P levels, with several patients having prolonged
stabilization of disease. The development of YELIVA(R) was funded to date
primarily by grants and contracts from U.S. federal and state government
agencies awarded to Apogee Biotechnology Corp., including the U.S. National
Cancer Institute, the U.S. Department of Health and Human Services'
Biomedical Advanced Research and Development Authority (BARDA), the U.S.
Department of Defense and the FDA Office of Orphan Products Development.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is a specialty biopharmaceutical